Use of echinocandins combined with clindamycin in Pneumocystis pneumonia: a case series of 14 patients.

IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Journal of Antimicrobial Chemotherapy Pub Date : 2024-11-13 DOI:10.1093/jac/dkae379
Idoia Bilbao, Iñigo Pineda Abel de la Cruz, Francisco de Asís Carmona-Torre, Mariano Rodríguez-Mateos, José Ramón Yuste Ara, Jose L Del Pozo
{"title":"Use of echinocandins combined with clindamycin in Pneumocystis pneumonia: a case series of 14 patients.","authors":"Idoia Bilbao, Iñigo Pineda Abel de la Cruz, Francisco de Asís Carmona-Torre, Mariano Rodríguez-Mateos, José Ramón Yuste Ara, Jose L Del Pozo","doi":"10.1093/jac/dkae379","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pneumocystis jirovecii pneumonia (PcP) is an opportunistic infection for which the standard of care is co-trimoxazole. However, safety concerns and intolerance may compromise its utility.</p><p><strong>Objectives: </strong>To evaluate the safety and efficacy of the combination of echinocandins and clindamycin to treat PcP.</p><p><strong>Patients and methods: </strong>We investigated 14 patients treated with a co-trimoxazole-free combined regimen that included echinocandins and clindamycin.</p><p><strong>Results: </strong>Clinical cure was achieved in 8 out of 14 patients, while 5 had a fatal outcome due to their primary disease; however, only one patient died due to PcP.</p><p><strong>Conclusions: </strong>Echinocandin and clindamycin may be a safe and effective alternative treatment for patients who cannot be given co-trimoxazole for PcP.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antimicrobial Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jac/dkae379","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pneumocystis jirovecii pneumonia (PcP) is an opportunistic infection for which the standard of care is co-trimoxazole. However, safety concerns and intolerance may compromise its utility.

Objectives: To evaluate the safety and efficacy of the combination of echinocandins and clindamycin to treat PcP.

Patients and methods: We investigated 14 patients treated with a co-trimoxazole-free combined regimen that included echinocandins and clindamycin.

Results: Clinical cure was achieved in 8 out of 14 patients, while 5 had a fatal outcome due to their primary disease; however, only one patient died due to PcP.

Conclusions: Echinocandin and clindamycin may be a safe and effective alternative treatment for patients who cannot be given co-trimoxazole for PcP.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在肺孢子菌肺炎中使用棘白菌素联合克林霉素:14 例患者的病例系列。
背景:肺孢子虫肺炎(PcP)是一种机会性感染,其标准疗法是联合三唑。然而,安全性问题和不耐受性可能会影响其效用:目的:评估棘白菌素和克林霉素联合治疗 PcP 的安全性和有效性:我们对14名患者进行了调查,他们接受了包括棘白菌素类和克林霉素在内的不含联合三唑的联合治疗方案:结果:14名患者中有8人获得临床治愈,5人因原发疾病而死亡;但只有1名患者死于PcP:结论:对于无法使用联合新诺明治疗 PcP 的患者,棘白菌素和克林霉素可能是一种安全有效的替代治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.20
自引率
5.80%
发文量
423
审稿时长
2-4 weeks
期刊介绍: The Journal publishes articles that further knowledge and advance the science and application of antimicrobial chemotherapy with antibiotics and antifungal, antiviral and antiprotozoal agents. The Journal publishes primarily in human medicine, and articles in veterinary medicine likely to have an impact on global health.
期刊最新文献
Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion. Efficacy and tolerability of high-dose cefalexin 45 mg/kg/dose (maximum 1.5 g) three times daily in children with bone and joint infections. Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting. Comment on: Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia. Insights into interspecies protein binding variability using clindamycin as an example.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1